MK-677 (Ibutamoren) vs HGH (Somatropin)
Ghrelin Mimetic · Recombinant Growth Hormone
Here is how these two compounds compare, based on published research, not marketing claims.
MK-677
An oral non-peptide ghrelin receptor agonist that triggers the pituitary to release the body's own growth hormone; not FDA-approved.
HGH
The recombinant human growth hormone itself, FDA-approved as somatropin under multiple brand names with decades of clinical use.
MK-677
134 studies
24 human trials
Not FDA-Approved
HGH
0 studies
0 human trials
Not FDA-Approved
What it does
MK-677
Delivers growth hormone signaling through a pill rather than an injection: the only secretagogue in this class with practical oral bioavailability. Hits the same ghrelin receptor as the injectable compounds, but in a form the gut can absorb. Clinical trials (most notably Murphy et al. and Nass et al.) documented sustained nightly growth hormone and IGF-1 elevation across the 24-hour cycle, alongside the appetite increase and changes in blood sugar handling that ultimately contributed to the failed Alzheimer's trials and the compound's research-only status today.
HGH
Replaces or supplements the body's natural growth hormone, the pituitary signal that controls cellular growth and tissue repair throughout the body. The recombinant human form, FDA-approved as somatropin under multiple brand names including Genotropin, Humatrope, and Norditropin.
How it works
MK-677
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland and stimulates growth hormone release. The mechanism is functionally identical to injectable GH secretagogues like ipamorelin and GHRP-6, but the molecule is engineered for oral bioavailability. The body responds to the GH-releasing signal whether the trigger arrives by injection or by mouth. The downstream effect is increased GH followed by increased IGF-1 production from the liver.
HGH
HGH is a 191-amino-acid protein hormone produced by the anterior pituitary gland. The recombinant pharmaceutical form is bioidentical to the body's own version. After injection, it travels through the bloodstream to the liver, where it stimulates production of insulin-like growth factor 1 (IGF-1), the downstream messenger that mediates most of HGH's effects on cellular growth, protein synthesis, and tissue repair. HGH also acts directly on adipose tissue (promoting lipolysis), bones, muscles, and the immune system.
How often
MK-677
Oral administration in research protocols. Published studies use daily oral dosing over periods ranging from 8 weeks to 24 weeks. MK-677 is not FDA-approved for any therapeutic indication; no approved product contains ibutamoren mesylate.
HGH
FDA-approved labeling specifies daily subcutaneous injection in clinical use, with dosing individualized to indication, age, weight, and IGF-1 response. Long-acting depot formulations approved more recently allow once-weekly administration in some contexts.
How strong
MK-677
The oral GH secretagogue. Multiple short-term controlled studies (8 weeks to 6 months) demonstrate GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements (Copinschi 1997 showed 50% increase in stage 4 sleep duration). Reversed diet-induced catabolism in healthy volunteers (Murphy 1998). Fat-free mass gains in obese men (Svensson 1998).
HGH
The reference standard for growth hormone interventions. FDA-approved for multiple indications spanning pediatric and adult use: pediatric growth hormone deficiency, adult GH deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, AIDS wasting, short bowel syndrome, and others. Decades of clinical use with extensive safety and efficacy data.
Main tradeoff
MK-677
Oral convenience versus metabolic side effects is the core trade-off. MK-677 raises appetite (ghrelin is the hunger hormone), may elevate blood glucose and reduce insulin sensitivity, and causes water retention. The 24-week Murphy 2008 elderly hip-fracture study was discontinued due to a congestive heart failure signal in that population, the most concerning safety finding in the published literature. Whether the elderly CHF signal applies to healthy younger populations is not established. The compound has not passed Phase III trials despite decades of investigation. Compared to ipamorelin (the selective injectable alternative), MK-677 lacks the clean hormonal selectivity profile.
HGH
Direct hormone replacement rather than stimulating endogenous release. The body's natural pulsatile pattern of GH secretion is replaced by the pharmacokinetic profile of the injection. Long-term safety in non-deficient populations using HGH for body composition or anti-aging purposes is poorly characterized. Off-label use of HGH for adult anti-aging or athletic performance is legally restricted in the United States under the Anabolic Steroid Control Act and FDA enforcement policies. Cost and supply considerations are substantial.
Best for
MK-677
- Research interest in oral GH secretagogue mechanisms compared to injectable alternatives
- Research comparing sustained GH elevation (MK-677) versus pulsatile release (ipamorelin, sermorelin)
- Research contexts where the oral-versus-injectable administration question is central
HGH
- Patients with diagnosed growth hormone deficiency in pediatric or adult populations under physician supervision
- Patients meeting FDA-approved indications including Turner syndrome, Prader-Willi syndrome, AIDS wasting, and short bowel syndrome
- Researchers comparing direct hormone replacement against strategies that stimulate the body's own GH release
How to choose
A good fit for MK-677
- Research on oral GH secretagogue mechanisms compared to direct hormone replacement
- Research contexts where injection avoidance is a primary consideration
- Research comparing sustained endogenous GH elevation versus exogenous replacement
A good fit for HGH
- Clinical treatment for diagnosed growth hormone deficiency under physician supervision
- Research contexts where FDA-approved status and decades of clinical validation are required
- Research comparing the reference standard against investigational GH-elevation strategies
Consider both across time
MK-677 and HGH represent fundamentally different approaches to growth hormone elevation. MK-677 stimulates the pituitary to release the body's own GH through ghrelin receptor activation; oral convenience but not FDA-approved and with an elderly cardiovascular safety signal requiring monitoring. HGH directly replaces the hormone the pituitary produces; the reference standard for GH interventions with FDA approval across multiple indications, but injection-only, costly, and with off-label adult anti-aging use legally restricted in the United States.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Ghrelin Receptor (GHS-R1a)
- Ghrelin Receptor (GHS-R1a) activates Pituitary Somatotrophs
- Pituitary Somatotrophs connects to Growth Hormone Release
- Growth Hormone Release stimulates Liver IGF-1 Production; GH Receptor (liver, muscle, adipose, bone) activates Liver IGF-1 Production
- Liver IGF-1 Production connects to IGF-1 Elevation
- GH Receptor (liver, muscle, adipose, bone)
- GH Receptor (liver, muscle, adipose, bone) connects to Direct Tissue Effects (lipolysis, bone, muscle)
- Liver IGF-1 Production connects to IGF-1 Mediated Growth and Repair
- Direct Tissue Effects (lipolysis, bone, muscle) connects to Body Composition Effects
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland to trigger growth hormone release; in pill form rather than injection.
HGH is the recombinant human growth hormone itself, bioidentical to the pituitary's natural product, replacing the body's own hormone directly.
Research Evidence
HGH has dramatically more clinical evidence: decades of randomized controlled trials and post-market surveillance across multiple FDA-approved indications including pediatric and adult GH deficiency, Turner syndrome, and AIDS wasting. MK-677 has multiple short-term controlled trials (8 to 24 weeks) demonstrating GH and IGF-1 elevation, body composition effects, bone turnover changes, and sleep quality improvements. The 24-week elderly hip-fracture study (Murphy 2008) was discontinued due to a congestive heart failure signal. For clinical GH replacement, HGH is the regulatory and evidence standard. For oral GH-elevation research, MK-677 has the most substantial data among non-injectable options.
- 1.
For diagnosed GH deficiency requiring replacement, HGH is the standard of care.
- 2.
For GH optimization without a deficiency diagnosis, MK-677 is more accessible.
- 3.
For minimizing regulatory and prescription barriers, MK-677 is available without prescription in many contexts.
- 4.
For precise GH dosing and medical monitoring, HGH provides more control.
Key Limitations
- •Not a fair comparison, HGH is an FDA-approved pharmaceutical, MK-677 is a research compound.
- •MK-677 cannot produce the same GH levels as exogenous HGH.
- •HGH requires prescription, medical monitoring, and significantly higher cost.
- •Long-term outcomes from MK-677 GH stimulation vs HGH replacement have not been compared.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
MK-677 (Ibutamoren)
"MK-677 increased my growth hormone levels significantly"
Supported by published data
"It made me hungry all the time and I gained fat"
Supported by published data
"I use it for better sleep and recovery"
Plausible but unproven
Safety Comparison
HGH has the most mature safety profile: decades of post-market surveillance from millions of prescriptions. MK-677's safety profile includes short-term trial data showing increased appetite (ghrelin is the hunger hormone), potential glucose and insulin sensitivity effects, and the 24-week elderly hip-fracture study CHF signal. Whether the elderly CHF signal applies to healthy younger populations is not established. Off-label HGH use for adult anti-aging is legally restricted under U.S. law. Neither compound's long-term safety for non-deficient anti-aging use is well-characterized.
MK-677 (Ibutamoren)
Increases appetite. May elevate blood glucose and insulin. Water retention. Not FDA-approved.
HGH (Somatropin)
Well-characterized. Side effects include joint pain, edema, carpal tunnel syndrome, insulin resistance. Requires medical monitoring. Misuse risks include acromegaly symptoms.
What the Research Suggests
HGH is the proven medical treatment. MK-677 is the accessible research alternative. They serve overlapping but different populations. HGH for diagnosed deficiency. MK-677 for optimization without prescription access.